NCT04667052View on ClinicalTrials.gov

A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

June 15, 2021

Study Completion Date

June 15, 2021

Conditions

Healthy

Interventions

DRUG

JNJ 64304500

Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.

DRUG

JNJ 64304500

Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation.

Trial Locations (1)

90630

WCCT Global, LLC, Cypress

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT04667052 - A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants | Biotech Hunter | Biotech Hunter